adjuvant therapies - versus control - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.22 [0.07, 0.67]< 10%1 study (1/-)99.6 %NAnot evaluable crucial-
death or transfer to ICU 0.70 [0.44, 1.12]< 10%1 study (1/-)93.1 %NAnot evaluable crucial-
deaths 0.49 [0.13, 1.87]< 182%2 studies (2/-)85.2 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.69 [0.43, 1.10]< 10%1 study (1/-)93.9 %NAnot evaluable important-
clinical improvement (28-day) 1.27 [1.03, 1.57]> 10%1 study (1/-)98.6 %NAnot evaluable important-
death or ventilation 0.76 [0.58, 1.00]< 111%2 studies (2/-)97.6 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.70 [0.32, 1.54]< 10%1 study (1/-)81.1 %NAnot evaluable important-
ICU admission 0.79 [0.48, 1.30]< 10%1 study (1/-)82.5 %NAnot evaluable non important-

safety endpoints 00

Major bleeding 1.80 [0.88, 3.67]< 10%1 study (1/-)5.3 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.